Quick Answer
Taysha Gene Therapies, Inc. reported R&D Expense of $86.40 million for fiscal year 2025.
Taysha Gene Therapies, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $86.40M | +30.9% |
| 2024 | $66.00M | +16.2% |
| 2023 | $56.78M | -37.7% |
| 2022 | $91.17M | -30.9% |
| 2021 | $131.94M | +313.7% |
| 2020 | $31.89M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.75M | +72.3% | +27.8% |
| June 30, 2025 | $20.14M | +33.6% | +29.4% |
| March 31, 2025 | $15.56M | -24.7% | +4.1% |
| September 30, 2024 | $14.95M | +26.8% | -0.8% |
| June 30, 2024 | $15.07M | -23.8% | -27.0% |
| March 31, 2024 | $20.66M | +65.1% | +75.2% |
| September 30, 2023 | $11.79M | -29.7% | -40.4% |
| June 30, 2023 | $19.79M | -15.8% | +58.2% |
- Taysha Gene Therapies, Inc. showed an increase of +30.9% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Taysha Gene Therapies, Inc.’s r&d expense has grown by 170.9% (from $31.89 million to $86.40 million).
- The most recent figure is from Taysha Gene Therapies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: